通过体内电穿孔递送的基于DNA的候选HIV疫苗可在健康志愿者中诱导针对HIV gp120的α4β7结合V2环的CD4反应。
A DNA-based candidate HIV vaccine delivered via in vivo electroporation induces CD4 responses toward the α4β7-binding V2 loop of HIV gp120 in healthy volunteers.
作者信息
Kopycinski Jakub, Cheeseman Hannah, Ashraf Ambreen, Gill Dilbinder, Hayes Peter, Hannaman Drew, Gilmour Jill, Cox Josephine H, Vasan Sandhya
机构信息
IAVI Human Immunology Laboratory, Imperial College, London, United Kingdom.
出版信息
Clin Vaccine Immunol. 2012 Sep;19(9):1557-9. doi: 10.1128/CVI.00327-12. Epub 2012 Jul 25.
Abstract
Administration of a clade C/B' candidate HIV-1 DNA vaccine, ADVAX, by in vivo electroporation (EP) was safe and more immunogenic than intramuscular administration without EP. The breadth and specificity of T-cell responses to full-length Env were mapped. Responses to multiple Env regions were induced, with most focusing on V3/C4 and V2 regions, including the α4β7 integrin-binding domain. The breadth of responses induced by this DNA vaccine regimen was comparable to that of viral-vectored vaccine regimens.
摘要
通过体内电穿孔（EP）接种C/B'亚型候选HIV-1 DNA疫苗ADVAX是安全的，且比无EP的肌肉注射免疫原性更强。对全长Env的T细胞反应的广度和特异性进行了图谱分析。诱导了对多个Env区域的反应，大多数集中在V3/C4和V2区域，包括α4β7整合素结合域。这种DNA疫苗方案诱导的反应广度与病毒载体疫苗方案相当。
相似文献
1
A DNA-based candidate HIV vaccine delivered via in vivo electroporation induces CD4 responses toward the α4β7-binding V2 loop of HIV gp120 in healthy volunteers.通过体内电穿孔递送的基于DNA的候选HIV疫苗可在健康志愿者中诱导针对HIV gp120的α4β7结合V2环的CD4反应。
Clin Vaccine Immunol. 2012 Sep;19(9):1557-9. doi: 10.1128/CVI.00327-12. Epub 2012 Jul 25.
2
Immunogenicity, safety, biodistribution and persistence of ADVAX, a prophylactic DNA vaccine for HIV-1, delivered by in vivo electroporation.ADVAX，一种用于预防 HIV-1 的预防性 DNA 疫苗，通过体内电穿孔递送的免疫原性、安全性、生物分布和持久性。
Vaccine. 2011 Jan 17;29(4):795-803. doi: 10.1016/j.vaccine.2010.11.011. Epub 2010 Nov 19.
3
In vivo electroporation in DNA-VLP prime-boost preferentially enhances HIV-1 envelope-specific IgG2a, neutralizing antibody and CD8 T cell responses.在DNA-病毒样颗粒初免-加强免疫中进行体内电穿孔可优先增强HIV-1包膜特异性IgG2a、中和抗体及CD8 T细胞反应。
Vaccine. 2017 Apr 11;35(16):2042-2051. doi: 10.1016/j.vaccine.2017.03.006. Epub 2017 Mar 17.
4
In vivo electroporation enhances the immunogenicity of an HIV-1 DNA vaccine candidate in healthy volunteers.体内电穿孔增强了健康志愿者中 HIV-1 DNA 疫苗候选物的免疫原性。
PLoS One. 2011;6(5):e19252. doi: 10.1371/journal.pone.0019252. Epub 2011 May 16.
5
HIV-DNA Given with or without Intradermal Electroporation Is Safe and Highly Immunogenic in Healthy Swedish HIV-1 DNA/MVA Vaccinees: A Phase I Randomized Trial.在健康的瑞典HIV-1 DNA/MVA疫苗接种者中，联合或不联合皮内电穿孔给予HIV-DNA是安全且具有高度免疫原性的：一项I期随机试验。
PLoS One. 2015 Jun 29;10(6):e0131748. doi: 10.1371/journal.pone.0131748. eCollection 2015.
6
Combined Skin and Muscle DNA Priming Provides Enhanced Humoral Responses to a Human Immunodeficency Virus Type 1 Clade C Envelope Vaccine.联合皮肤和肌肉 DNA 初免可增强对 HIV-1 型 C 群包膜疫苗的体液免疫应答。
Hum Gene Ther. 2018 Sep;29(9):1011-1028. doi: 10.1089/hum.2018.075.
7
Identification of New Regions in HIV-1 gp120 Variable 2 and 3 Loops that Bind to α4β7 Integrin Receptor.鉴定HIV-1 gp120可变区2和3环中与α4β7整合素受体结合的新区域。
PLoS One. 2015 Dec 1;10(12):e0143895. doi: 10.1371/journal.pone.0143895. eCollection 2015.
8
HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine.HIV-1 gp120与改良安卡拉痘苗病毒（MVA）gp140加强免疫原增强DNA/MVA HIV-1疫苗的免疫原性。
J Virol. 2017 Nov 30;91(24). doi: 10.1128/JVI.01077-17. Print 2017 Dec 15.
9
Potent CD4+ T cell responses elicited by a bicistronic HIV-1 DNA vaccine expressing gp120 and GM-CSF.由表达gp120和GM-CSF的双顺反子HIV-1 DNA疫苗引发的强效CD4 + T细胞反应。
J Immunol. 2002 Jan 15;168(2):562-8. doi: 10.4049/jimmunol.168.2.562.
10
Induction of Identical IgG HIV-1 Envelope Epitope Recognition Patterns After Initial HIVIS-DNA/MVA-CMDR Immunization and a Late MVA-CMDR Boost.初次 HIVIS-DNA/MVA-CMDR 免疫接种和晚期 MVA-CMDR 加强免疫后诱导相同的 IgG HIV-1 包膜表位识别模式。
Front Immunol. 2020 Apr 28;11:719. doi: 10.3389/fimmu.2020.00719. eCollection 2020.
引用本文的文献
1
Development and Evaluation of an Ebola Virus Glycoprotein Mucin-Like Domain Replacement System as a New Dendritic Cell-Targeting Vaccine Approach against HIV-1.埃博拉病毒糖蛋白粘蛋白样结构域替代系统的构建与评价：一种新型树突状细胞靶向 HIV-1 疫苗策略
J Virol. 2021 Jul 12;95(15):e0236820. doi: 10.1128/JVI.02368-20.
2
Immunogenicity evaluation of the HIV-1 Tat containing polyepitope DNA vaccine adjuvanted with CpG-ODNs in mice.含HIV-1反式激活因子的多表位DNA疫苗与CpG寡脱氧核苷酸联合佐剂在小鼠体内的免疫原性评估
Iran J Basic Med Sci. 2021 Mar;24(3):377-382. doi: 10.22038/ijbms.2021.52890.11923.
3
DNA Vaccination by Electroporation Amplifies Broadly Cross-Restricted Public TCR Clonotypes Shared with HIV Controllers.通过电穿孔进行的DNA疫苗接种可扩增与HIV控制者共有的广泛交叉受限的公共TCR克隆型。
J Immunol. 2017 Nov 15;199(10):3437-3452. doi: 10.4049/jimmunol.1700953. Epub 2017 Oct 9.
4
HIV Env conserved element DNA vaccine alters immunodominance in macaques.HIV Env 保守元件 DNA 疫苗改变猕猴中的免疫优势。
Hum Vaccin Immunother. 2017 Dec 2;13(12):2859-2871. doi: 10.1080/21645515.2017.1339852. Epub 2017 Jul 5.
5
An Approach for a Synthetic CTL Vaccine Design against Zika Flavivirus Using Class I and Class II Epitopes Identified by Computer Modeling.一种利用计算机建模鉴定的I类和II类表位设计针对寨卡黄病毒的合成细胞毒性T淋巴细胞疫苗的方法。
Front Immunol. 2017 Jun 9;8:640. doi: 10.3389/fimmu.2017.00640. eCollection 2017.
6
A phase 1, randomized, controlled dose-escalation study of EP-1300 polyepitope DNA vaccine against Plasmodium falciparum malaria administered via electroporation.一项关于通过电穿孔接种的EP - 1300多表位DNA疫苗抗恶性疟原虫疟疾的1期随机对照剂量递增研究。
Vaccine. 2016 Nov 4;34(46):5571-5578. doi: 10.1016/j.vaccine.2016.09.041. Epub 2016 Sep 30.
7
HIV DNA Vaccine: Stepwise Improvements Make a Difference.HIV DNA疫苗：逐步改进产生显著效果。
Vaccines (Basel). 2014 May 14;2(2):354-79. doi: 10.3390/vaccines2020354.
8
Elucidating the Kinetics of Expression and Immune Cell Infiltration Resulting from Plasmid Gene Delivery Enhanced by Surface Dermal Electroporation.阐明由表面真皮电穿孔增强的质粒基因递送所导致的表达动力学和免疫细胞浸润。
Vaccines (Basel). 2013 Aug 28;1(3):384-97. doi: 10.3390/vaccines1030384.
9
Enhanced Delivery and Potency of Self-Amplifying mRNA Vaccines by Electroporation in Situ.通过原位电穿孔增强自我扩增mRNA疫苗的递送和效力。
Vaccines (Basel). 2013 Aug 22;1(3):367-83. doi: 10.3390/vaccines1030367.
10
Skin Transfection Patterns and Expression Kinetics of Electroporation-Enhanced Plasmid Delivery Using the CELLECTRA-3P, a Portable Next-Generation Dermal Electroporation Device.使用便携式下一代真皮电穿孔设备CELLECTRA-3P进行电穿孔增强质粒递送的皮肤转染模式和表达动力学
Hum Gene Ther Methods. 2015 Aug;26(4):134-46. doi: 10.1089/hgtb.2015.020.
本文引用的文献
1
The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope.泰国 III 期临床试验（RV144）疫苗方案诱导的 T 细胞反应优先针对 HIV-1 包膜 V2 区的表位。
J Immunol. 2012 May 15;188(10):5166-76. doi: 10.4049/jimmunol.1102756. Epub 2012 Apr 23.
2
Immune-correlates analysis of an HIV-1 vaccine efficacy trial.HIV-1 疫苗功效试验的免疫相关性分析。
N Engl J Med. 2012 Apr 5;366(14):1275-86. doi: 10.1056/NEJMoa1113425.
3
Enhanced control of pathogenic Simian immunodeficiency virus SIVmac239 replication in macaques immunized with an interleukin-12 plasmid and a DNA prime-viral vector boost vaccine regimen.增强免疫白细胞介素 12 质粒和 DNA 初免-病毒载体加强疫苗方案免疫恒河猴对致病性猿猴免疫缺陷病毒 SIVmac239 复制的控制。
J Virol. 2011 Sep;85(18):9578-87. doi: 10.1128/JVI.05060-11. Epub 2011 Jul 6.
4
Mapping HIV-1 vaccine induced T-cell responses: bias towards less-conserved regions and potential impact on vaccine efficacy in the Step study.绘制 HIV-1 疫苗诱导的 T 细胞反应图谱：偏向于较少保守的区域，以及对 Step 研究中疫苗效力的潜在影响。
PLoS One. 2011;6(6):e20479. doi: 10.1371/journal.pone.0020479. Epub 2011 Jun 10.
5
In vivo electroporation enhances the immunogenicity of an HIV-1 DNA vaccine candidate in healthy volunteers.体内电穿孔增强了健康志愿者中 HIV-1 DNA 疫苗候选物的免疫原性。
PLoS One. 2011;6(5):e19252. doi: 10.1371/journal.pone.0019252. Epub 2011 May 16.
6
Electroporation delivery of DNA vaccines: prospects for success.电穿孔法递送 DNA 疫苗：成功的前景。
Curr Opin Immunol. 2011 Jun;23(3):421-9. doi: 10.1016/j.coi.2011.03.008. Epub 2011 Apr 27.
7
Equivalence of ELISpot assays demonstrated between major HIV network laboratories.主要 HIV 网络实验室之间证明了 ELISpot 检测法的等效性。
PLoS One. 2010 Dec 14;5(12):e14330. doi: 10.1371/journal.pone.0014330.
8
Immunogenicity, safety, biodistribution and persistence of ADVAX, a prophylactic DNA vaccine for HIV-1, delivered by in vivo electroporation.ADVAX，一种用于预防 HIV-1 的预防性 DNA 疫苗，通过体内电穿孔递送的免疫原性、安全性、生物分布和持久性。
Vaccine. 2011 Jan 17;29(4):795-803. doi: 10.1016/j.vaccine.2010.11.011. Epub 2010 Nov 19.
9
Increasing CTL targeting of conserved sequences during early HIV-1 infection is correlated to decreasing viremia.在早期HIV-1感染期间，细胞毒性T淋巴细胞（CTL）对保守序列靶向性的增加与病毒血症的降低相关。
AIDS Res Hum Retroviruses. 2011 Apr;27(4):391-8. doi: 10.1089/aid.2010.0183. Epub 2010 Nov 18.
10
Mutation at a single position in the V2 domain of the HIV-1 envelope protein confers neutralization sensitivity to a highly neutralization-resistant virus.HIV-1 包膜蛋白 V2 结构域单个位置的突变使对高度抗中和的病毒具有中和敏感性。
J Virol. 2010 Nov;84(21):11200-9. doi: 10.1128/JVI.00790-10. Epub 2010 Aug 11.
Zotero 插件